Drug Trial Radar · NCT04821089
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
727
Planned (sponsor's estimate)
Start
Apr 6, 2021
Primary completion
Aug 19, 2027
Study completion Aug 19, 2027
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines. This study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants. Stage 1 (phase Ib \& II) * Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL) * Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport * Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study). Stage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL) Stage 3 (phase II) \- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)
Conditions
- Moderate to Severe Upper Facial Lines
Interventions
CorabotaseBiological
Stage 1: Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region. Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions. Stage 3: One single injection will be injected locally into several sites across the upper facial area.
IPN10200 PlaceboBiological
Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region. Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions. Stage 3: One single injection will be injected locally into several sites across the upper facial area.
DysportBiological
Single administration of study intervention in stage 1 / step 2 and 3 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAEs) at each doseTime frame: From the baseline to the end of the study (9 months)
- Incidence of serious adverse events (SAEs) at each doseTime frame: From the baseline to the end of the study (9 months)
- Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)Time frame: From the baseline to the end of the study (9 months)
- Response to treatment at Stage 2 for the FHL groupTime frame: At Week 4
- Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL groupTime frame: At Week 4
- Response to treatment at Stage 2 for the LCL groupTime frame: At Week 4
- Percentage of Participants With Clinically Significant Changes from baseline in Vital SignsTime frame: From the baseline to the end of the study (6 years, 5 months)
- Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readingsTime frame: From the baseline to the end of the study (6 years, 5 months)
- Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.Time frame: From the baseline to the end of the study (6 years, 5 months)
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
MEDITI - Clinique Del Mar
Antibes, France
Aimed S.A.S
Lyon, France
Clinique de Chirurgie Esthétique Iéna
Paris, France
CRS Clinical Research Services Berlin GMBH
Berlin, Germany
Interdisciplinary Study Association
Berlin, Germany
ROSENPARK RESEARCH GmbH
Darmstadt, Germany
Privatpraxis Dr. Hilton & Partner
Düsseldorf, Germany
Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft
Hamburg, Germany
Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow
Mahlow, Germany
Interdisciplinary Study Association
Kassel, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.